Fulcrum therapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

Cambridge, mass., march 22, 2024 (globe newswire) -- fulcrum therapeutics, inc.® (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to patrick horn, m.d., ph.d., the company's newly appointed chief medical officer. fulcrum granted stock options to purchase shares of the company's common stock pursuant to the company's 2022 inducement stock incentive plan, as amended, or the plan, as an inducement material to the new employees entering into employment with fulcrum in accordance with nasdaq listing rule 5635(c)(4).
FULC Ratings Summary
FULC Quant Ranking